Review



cd69 vioblue  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Miltenyi Biotec cd69 vioblue
    Cd69 Vioblue, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 89 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd69/CD69+Antibody%2C+anti-human%2C+REAfinity/10__3389_slash_fimmu__2026__1844781-143-30-32
    Average 93 stars, based on 89 article reviews
    cd69 vioblue - by Bioz Stars, 2026-09
    93/100 stars

    Images

    Related Articles

    Single Cell:

    Article Title: The Role of Glycosphingolipids in Autoimmune Manifestations and Myeloma in Gaucher Disease
    Article Snippet: .. Single cell suspensions were stained with the following antibodies: anti-mouse antibodies CD45R/B220 (Thermo Fisher Scientific Cat# 15-0451-82, RRID:AB_468752), CD1d (Thermo Fisher Scientific Cat# 64-0011-82, RRID:AB_2688078), NK1.1 (Thermo Fisher Scientific Cat# 64-5941-82, RRID:AB_2662737), CD4 (BD Biosciences Cat# 563727, RRID:AB_2728707), CD8α (130-097-025, Miltenyi Biotec), TCR V β 10 ((Thermo Fisher Scientific Cat# 11-5805-80, RRID:AB_2043882), CD25 (BD Biosciences Cat# 561257, RRID:AB_10611871), CD44 (BioLegend Cat# 103027, RRID:AB_830784), CD69 (Miltenyi Biotec Cat# 130-103-946, RRID:AB_2659083), IgM (BD Biosciences Cat# 563837, RRID:AB_2869524), IgD (BD Biosciences Cat# 565348, RRID:AB_2739201), CD23, CD21, CD19, CD3, CD11b. .. Analysis was performed using BD Fortessa Analyser (BD Biosciences) and analysed with FlowJo software (BD Biosciences

    Staining:

    Article Title: The Role of Glycosphingolipids in Autoimmune Manifestations and Myeloma in Gaucher Disease
    Article Snippet: .. Single cell suspensions were stained with the following antibodies: anti-mouse antibodies CD45R/B220 (Thermo Fisher Scientific Cat# 15-0451-82, RRID:AB_468752), CD1d (Thermo Fisher Scientific Cat# 64-0011-82, RRID:AB_2688078), NK1.1 (Thermo Fisher Scientific Cat# 64-5941-82, RRID:AB_2662737), CD4 (BD Biosciences Cat# 563727, RRID:AB_2728707), CD8α (130-097-025, Miltenyi Biotec), TCR V β 10 ((Thermo Fisher Scientific Cat# 11-5805-80, RRID:AB_2043882), CD25 (BD Biosciences Cat# 561257, RRID:AB_10611871), CD44 (BioLegend Cat# 103027, RRID:AB_830784), CD69 (Miltenyi Biotec Cat# 130-103-946, RRID:AB_2659083), IgM (BD Biosciences Cat# 563837, RRID:AB_2869524), IgD (BD Biosciences Cat# 565348, RRID:AB_2739201), CD23, CD21, CD19, CD3, CD11b. .. Analysis was performed using BD Fortessa Analyser (BD Biosciences) and analysed with FlowJo software (BD Biosciences

    Article Title: A novel Vδ1 engager targeting CD19 enhances human Vδ1 γδ T cell responses against CLL and CD19+ hematological malignancies.
    Article Snippet: γδ T cells are associated with favorable outcomes in many cancers likely through a mechanism of stress-directed cytotoxicity and antitumor cytokine production.. Vδ1 γδ T cells are especially promising for immunotherapy due to their broad stress recognition and resistance to activation-induced cell death.. Here, we generate a CD19 engager incorporating a novel Vδ1 binding moiety as proof-of-concept for treating CD19 cancers, including Chronic Lymphocytic Leukemia (CLL).

    Article Title: Novel bispecific T-cell engagers overcoming acquired EGFR resistance.
    Article Snippet: For analysis of TCE-binding to CD3+ splenocytes isolated from BALB/c mice, cells were stained with FITC-coupled anti-mouse-CD3 antibody (Miltenyi Biotec #130–119-758). .. For analysis of early T-cell activation for co-cultures of CT-26 cells expressing human EGFRwt and splenocytes isolated from BALB/ c mice, T cells were stained with antibodies directed against mouse CD3 (Miltenyi Biotec #130–119-758), CD4 (Miltenyi Biotec #130–118-568), CD8 (Miltenyi Biotec #130–123-781) and CD69 (Miltenyi Biotec #130–115-461). ..

    Article Title: CliniMACS Prodigy Manufacturing of Switchable, AND-Gate CAR T Cells.
    Article Snippet: .. For phenotypic analysis, 0.2 × 106 cells were stained with monoclonal Abs (mAbs) against CD4, CD8, CD45RO, CD69, PD-1, Tim-3, Lag-3 (all purchased from Miltenyi Biotec GmbH), and CD62L (BioLegend, San Diego, CA, USA) for 15 min. To determine the percentage of cells expressing the respective RevCAR construct, 0.2 × 106 cells were incubated with 0.25 μg of the anti-La mAb (5B9) [45] or the anti-La mAb (7B6) [46] for 1 h, followed by staining with a fluorescently labeled secondary goat anti-mouse IgG Ab (BioLegend) for 30 min. All staining steps were performed at 4 ◦C in the dark. .. Stained cells were analyzed by applying MACSQuant® Analyzer 10 and MACSQuantify® software (both from Miltenyi Biotec GmbH).

    Flow Cytometry:

    Article Title: A novel Vδ1 engager targeting CD19 enhances human Vδ1 γδ T cell responses against CLL and CD19+ hematological malignancies.
    Article Snippet: γδ T cells are associated with favorable outcomes in many cancers likely through a mechanism of stress-directed cytotoxicity and antitumor cytokine production.. Vδ1 γδ T cells are especially promising for immunotherapy due to their broad stress recognition and resistance to activation-induced cell death.. Here, we generate a CD19 engager incorporating a novel Vδ1 binding moiety as proof-of-concept for treating CD19 cancers, including Chronic Lymphocytic Leukemia (CLL).

    Activation Assay:

    Article Title: Novel bispecific T-cell engagers overcoming acquired EGFR resistance.
    Article Snippet: For analysis of TCE-binding to CD3+ splenocytes isolated from BALB/c mice, cells were stained with FITC-coupled anti-mouse-CD3 antibody (Miltenyi Biotec #130–119-758). .. For analysis of early T-cell activation for co-cultures of CT-26 cells expressing human EGFRwt and splenocytes isolated from BALB/ c mice, T cells were stained with antibodies directed against mouse CD3 (Miltenyi Biotec #130–119-758), CD4 (Miltenyi Biotec #130–118-568), CD8 (Miltenyi Biotec #130–123-781) and CD69 (Miltenyi Biotec #130–115-461). ..

    Expressing:

    Article Title: Novel bispecific T-cell engagers overcoming acquired EGFR resistance.
    Article Snippet: For analysis of TCE-binding to CD3+ splenocytes isolated from BALB/c mice, cells were stained with FITC-coupled anti-mouse-CD3 antibody (Miltenyi Biotec #130–119-758). .. For analysis of early T-cell activation for co-cultures of CT-26 cells expressing human EGFRwt and splenocytes isolated from BALB/ c mice, T cells were stained with antibodies directed against mouse CD3 (Miltenyi Biotec #130–119-758), CD4 (Miltenyi Biotec #130–118-568), CD8 (Miltenyi Biotec #130–123-781) and CD69 (Miltenyi Biotec #130–115-461). ..

    Article Title: CliniMACS Prodigy Manufacturing of Switchable, AND-Gate CAR T Cells.
    Article Snippet: .. For phenotypic analysis, 0.2 × 106 cells were stained with monoclonal Abs (mAbs) against CD4, CD8, CD45RO, CD69, PD-1, Tim-3, Lag-3 (all purchased from Miltenyi Biotec GmbH), and CD62L (BioLegend, San Diego, CA, USA) for 15 min. To determine the percentage of cells expressing the respective RevCAR construct, 0.2 × 106 cells were incubated with 0.25 μg of the anti-La mAb (5B9) [45] or the anti-La mAb (7B6) [46] for 1 h, followed by staining with a fluorescently labeled secondary goat anti-mouse IgG Ab (BioLegend) for 30 min. All staining steps were performed at 4 ◦C in the dark. .. Stained cells were analyzed by applying MACSQuant® Analyzer 10 and MACSQuantify® software (both from Miltenyi Biotec GmbH).

    Isolation:

    Article Title: Novel bispecific T-cell engagers overcoming acquired EGFR resistance.
    Article Snippet: For analysis of TCE-binding to CD3+ splenocytes isolated from BALB/c mice, cells were stained with FITC-coupled anti-mouse-CD3 antibody (Miltenyi Biotec #130–119-758). .. For analysis of early T-cell activation for co-cultures of CT-26 cells expressing human EGFRwt and splenocytes isolated from BALB/ c mice, T cells were stained with antibodies directed against mouse CD3 (Miltenyi Biotec #130–119-758), CD4 (Miltenyi Biotec #130–118-568), CD8 (Miltenyi Biotec #130–123-781) and CD69 (Miltenyi Biotec #130–115-461). ..

    Construct:

    Article Title: CliniMACS Prodigy Manufacturing of Switchable, AND-Gate CAR T Cells.
    Article Snippet: .. For phenotypic analysis, 0.2 × 106 cells were stained with monoclonal Abs (mAbs) against CD4, CD8, CD45RO, CD69, PD-1, Tim-3, Lag-3 (all purchased from Miltenyi Biotec GmbH), and CD62L (BioLegend, San Diego, CA, USA) for 15 min. To determine the percentage of cells expressing the respective RevCAR construct, 0.2 × 106 cells were incubated with 0.25 μg of the anti-La mAb (5B9) [45] or the anti-La mAb (7B6) [46] for 1 h, followed by staining with a fluorescently labeled secondary goat anti-mouse IgG Ab (BioLegend) for 30 min. All staining steps were performed at 4 ◦C in the dark. .. Stained cells were analyzed by applying MACSQuant® Analyzer 10 and MACSQuantify® software (both from Miltenyi Biotec GmbH).

    Incubation:

    Article Title: CliniMACS Prodigy Manufacturing of Switchable, AND-Gate CAR T Cells.
    Article Snippet: .. For phenotypic analysis, 0.2 × 106 cells were stained with monoclonal Abs (mAbs) against CD4, CD8, CD45RO, CD69, PD-1, Tim-3, Lag-3 (all purchased from Miltenyi Biotec GmbH), and CD62L (BioLegend, San Diego, CA, USA) for 15 min. To determine the percentage of cells expressing the respective RevCAR construct, 0.2 × 106 cells were incubated with 0.25 μg of the anti-La mAb (5B9) [45] or the anti-La mAb (7B6) [46] for 1 h, followed by staining with a fluorescently labeled secondary goat anti-mouse IgG Ab (BioLegend) for 30 min. All staining steps were performed at 4 ◦C in the dark. .. Stained cells were analyzed by applying MACSQuant® Analyzer 10 and MACSQuantify® software (both from Miltenyi Biotec GmbH).

    Labeling:

    Article Title: CliniMACS Prodigy Manufacturing of Switchable, AND-Gate CAR T Cells.
    Article Snippet: .. For phenotypic analysis, 0.2 × 106 cells were stained with monoclonal Abs (mAbs) against CD4, CD8, CD45RO, CD69, PD-1, Tim-3, Lag-3 (all purchased from Miltenyi Biotec GmbH), and CD62L (BioLegend, San Diego, CA, USA) for 15 min. To determine the percentage of cells expressing the respective RevCAR construct, 0.2 × 106 cells were incubated with 0.25 μg of the anti-La mAb (5B9) [45] or the anti-La mAb (7B6) [46] for 1 h, followed by staining with a fluorescently labeled secondary goat anti-mouse IgG Ab (BioLegend) for 30 min. All staining steps were performed at 4 ◦C in the dark. .. Stained cells were analyzed by applying MACSQuant® Analyzer 10 and MACSQuantify® software (both from Miltenyi Biotec GmbH).



    Similar Products

    cd69 vioblue  (Miltenyi Biotec)
    93
    Miltenyi Biotec cd69 vioblue
    Cd69 Vioblue, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd69/CD69+Antibody%2C+anti-human%2C+REAfinity/10__3389_slash_fimmu__2026__1844781-143-30-32
    Average 93 stars, based on 1 article reviews
    cd69 vioblue - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    cd69  (Miltenyi Biotec)
    93
    Miltenyi Biotec cd69
    Cd69, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd69/CD69+Antibody%2C+anti-human%2C+REAfinity/pm42455847-67-100-102
    Average 93 stars, based on 1 article reviews
    cd69 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    cd69 antibody, anti-human, reafinity  (Miltenyi Biotec)
    93
    Miltenyi Biotec cd69 antibody, anti-human, reafinity
    Cd69 Antibody, Anti Human, Reafinity, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd69/CD69+Antibody%2C+anti-human%2C+REAfinity/custom%40130-124-326%4042447860
    Average 93 stars, based on 1 article reviews
    cd69 antibody, anti-human, reafinity - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    anti human cd69  (Miltenyi Biotec)
    94
    Miltenyi Biotec anti human cd69
    Characterization of CD8 + cells in IFN- and OCRE-treated patients with multiple sclerosis (pwMS) undergoing BNT162b2 mRNA SARS-CoV-2 vaccination. Cumulative data of flow cytometry analysis showing cell percentage of (a, g) CD8 + , (b, h) CD154 + , (c, i) <t>CD69</t> + , (d, j) OX40 + , (e, k) TIGIT + , (f, l) CD62L + in peripheral blood mononuclear cells (PBMCs) of (a-f) IFN- and (g-l) OCRE-treated pwMS before (T0), 21 days after the first (T1) and the second (T2) vaccine dose. (a-f) IFN: T0: n=10; T1: n=10; T2: n= 10; (g-l) OCRE: T0: n=10; T1: n=10; T2: n= 9. Each data point represents a distinct individual (i.e., an independent biological sample). Data are presented as median values. Statistical analysis was performed by using the Wilcoxon signed-rank test (two tails); * p ≤ 0.05; ** p ≤ 0.01.
    Anti Human Cd69, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd69/CD69+Antibody%2C+anti-human/pmc13314487-83-41-43
    Average 94 stars, based on 1 article reviews
    anti human cd69 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    anti cd69 affibody zcam241  (Affibody)
    86
    Affibody anti cd69 affibody zcam241
    Characterization of CD8 + cells in IFN- and OCRE-treated patients with multiple sclerosis (pwMS) undergoing BNT162b2 mRNA SARS-CoV-2 vaccination. Cumulative data of flow cytometry analysis showing cell percentage of (a, g) CD8 + , (b, h) CD154 + , (c, i) <t>CD69</t> + , (d, j) OX40 + , (e, k) TIGIT + , (f, l) CD62L + in peripheral blood mononuclear cells (PBMCs) of (a-f) IFN- and (g-l) OCRE-treated pwMS before (T0), 21 days after the first (T1) and the second (T2) vaccine dose. (a-f) IFN: T0: n=10; T1: n=10; T2: n= 10; (g-l) OCRE: T0: n=10; T1: n=10; T2: n= 9. Each data point represents a distinct individual (i.e., an independent biological sample). Data are presented as median values. Statistical analysis was performed by using the Wilcoxon signed-rank test (two tails); * p ≤ 0.05; ** p ≤ 0.01.
    Anti Cd69 Affibody Zcam241, supplied by Affibody, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd69/affibody+molecules+zcam241/pm42275072-150-19-20
    Average 86 stars, based on 1 article reviews
    anti cd69 affibody zcam241 - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    cd69  (Affibody)
    86
    Affibody cd69
    Characterization of CD8 + cells in IFN- and OCRE-treated patients with multiple sclerosis (pwMS) undergoing BNT162b2 mRNA SARS-CoV-2 vaccination. Cumulative data of flow cytometry analysis showing cell percentage of (a, g) CD8 + , (b, h) CD154 + , (c, i) <t>CD69</t> + , (d, j) OX40 + , (e, k) TIGIT + , (f, l) CD62L + in peripheral blood mononuclear cells (PBMCs) of (a-f) IFN- and (g-l) OCRE-treated pwMS before (T0), 21 days after the first (T1) and the second (T2) vaccine dose. (a-f) IFN: T0: n=10; T1: n=10; T2: n= 10; (g-l) OCRE: T0: n=10; T1: n=10; T2: n= 9. Each data point represents a distinct individual (i.e., an independent biological sample). Data are presented as median values. Statistical analysis was performed by using the Wilcoxon signed-rank test (two tails); * p ≤ 0.05; ** p ≤ 0.01.
    Cd69, supplied by Affibody, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd69/affibody+molecules+zcam241/pm42275072-39-5-6
    Average 86 stars, based on 1 article reviews
    cd69 - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    anti cd69 apc vio 770  (Miltenyi Biotec)
    94
    Miltenyi Biotec anti cd69 apc vio 770
    Characterization of CD8 + cells in IFN- and OCRE-treated patients with multiple sclerosis (pwMS) undergoing BNT162b2 mRNA SARS-CoV-2 vaccination. Cumulative data of flow cytometry analysis showing cell percentage of (a, g) CD8 + , (b, h) CD154 + , (c, i) <t>CD69</t> + , (d, j) OX40 + , (e, k) TIGIT + , (f, l) CD62L + in peripheral blood mononuclear cells (PBMCs) of (a-f) IFN- and (g-l) OCRE-treated pwMS before (T0), 21 days after the first (T1) and the second (T2) vaccine dose. (a-f) IFN: T0: n=10; T1: n=10; T2: n= 10; (g-l) OCRE: T0: n=10; T1: n=10; T2: n= 9. Each data point represents a distinct individual (i.e., an independent biological sample). Data are presented as median values. Statistical analysis was performed by using the Wilcoxon signed-rank test (two tails); * p ≤ 0.05; ** p ≤ 0.01.
    Anti Cd69 Apc Vio 770, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd69/KIR2D+Antibody%2C+anti-human%2C+REAfinity/pmc13236643-54-38-53
    Average 94 stars, based on 1 article reviews
    anti cd69 apc vio 770 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Characterization of CD8 + cells in IFN- and OCRE-treated patients with multiple sclerosis (pwMS) undergoing BNT162b2 mRNA SARS-CoV-2 vaccination. Cumulative data of flow cytometry analysis showing cell percentage of (a, g) CD8 + , (b, h) CD154 + , (c, i) CD69 + , (d, j) OX40 + , (e, k) TIGIT + , (f, l) CD62L + in peripheral blood mononuclear cells (PBMCs) of (a-f) IFN- and (g-l) OCRE-treated pwMS before (T0), 21 days after the first (T1) and the second (T2) vaccine dose. (a-f) IFN: T0: n=10; T1: n=10; T2: n= 10; (g-l) OCRE: T0: n=10; T1: n=10; T2: n= 9. Each data point represents a distinct individual (i.e., an independent biological sample). Data are presented as median values. Statistical analysis was performed by using the Wilcoxon signed-rank test (two tails); * p ≤ 0.05; ** p ≤ 0.01.

    Journal: Frontiers in Immunology

    Article Title: Multiple sclerosis patients under treatment with interferon β1-a or ocrelizumab exhibit different T and B cell responses to SARS-CoV-2 vaccine

    doi: 10.3389/fimmu.2026.1773417

    Figure Lengend Snippet: Characterization of CD8 + cells in IFN- and OCRE-treated patients with multiple sclerosis (pwMS) undergoing BNT162b2 mRNA SARS-CoV-2 vaccination. Cumulative data of flow cytometry analysis showing cell percentage of (a, g) CD8 + , (b, h) CD154 + , (c, i) CD69 + , (d, j) OX40 + , (e, k) TIGIT + , (f, l) CD62L + in peripheral blood mononuclear cells (PBMCs) of (a-f) IFN- and (g-l) OCRE-treated pwMS before (T0), 21 days after the first (T1) and the second (T2) vaccine dose. (a-f) IFN: T0: n=10; T1: n=10; T2: n= 10; (g-l) OCRE: T0: n=10; T1: n=10; T2: n= 9. Each data point represents a distinct individual (i.e., an independent biological sample). Data are presented as median values. Statistical analysis was performed by using the Wilcoxon signed-rank test (two tails); * p ≤ 0.05; ** p ≤ 0.01.

    Article Snippet: After the stimulation, cells were washed and surface stained for 20 minutes at 4 °C with the following antibodies: BV510-conjugated anti-human CD3 (Miltenyi, clone: BW264/56), APC-conjugated anti-human CD134 (OX40) (BD Pharmigen, clone: ACT35), APC-H7-conjugated anti-human CD4 (BD Pharmigen, clone: RPA-T4), PE-conjugated anti-human CD69 (Miltenyi, clone: FN50), PE-Cy 7-conjugated anti-human CD8 (BD Horizon, clone: RPA-T8).

    Techniques: Flow Cytometry

    Evaluation of CD4 + cells in IFN- and OCRE-treated patients with multiple sclerosis (pwMS) undergoing BNT162b2 mRNA SARS-CoV-2 vaccination. Percentage of (a, g) CD4 + , (b, h) CD154 + , (c, i) CD69 + , (d, j) OX40 + , (e, k) TIGIT + , (f, l) CD62L + cells in peripheral blood mononuclear cells (PBMCs) of (a, f) IFN- and (g, l) OCRE-treated pwMS before (T0), 21 days after the first (T1) and the second (T2) vaccine dose. (a-f) IFN: T0: n=10; T1: n=10; T2: n= 10; (g-l) OCRE: T0: n=10; T1: n=10; T2: n= 9. Each data point represents a distinct individual (i.e., an independent biological sample). Data are presented as median values. Statistical analysis was performed by using the Wilcoxon signed-rank test (two tails); * p ≤ 0.05; ** p ≤ 0.01.

    Journal: Frontiers in Immunology

    Article Title: Multiple sclerosis patients under treatment with interferon β1-a or ocrelizumab exhibit different T and B cell responses to SARS-CoV-2 vaccine

    doi: 10.3389/fimmu.2026.1773417

    Figure Lengend Snippet: Evaluation of CD4 + cells in IFN- and OCRE-treated patients with multiple sclerosis (pwMS) undergoing BNT162b2 mRNA SARS-CoV-2 vaccination. Percentage of (a, g) CD4 + , (b, h) CD154 + , (c, i) CD69 + , (d, j) OX40 + , (e, k) TIGIT + , (f, l) CD62L + cells in peripheral blood mononuclear cells (PBMCs) of (a, f) IFN- and (g, l) OCRE-treated pwMS before (T0), 21 days after the first (T1) and the second (T2) vaccine dose. (a-f) IFN: T0: n=10; T1: n=10; T2: n= 10; (g-l) OCRE: T0: n=10; T1: n=10; T2: n= 9. Each data point represents a distinct individual (i.e., an independent biological sample). Data are presented as median values. Statistical analysis was performed by using the Wilcoxon signed-rank test (two tails); * p ≤ 0.05; ** p ≤ 0.01.

    Article Snippet: After the stimulation, cells were washed and surface stained for 20 minutes at 4 °C with the following antibodies: BV510-conjugated anti-human CD3 (Miltenyi, clone: BW264/56), APC-conjugated anti-human CD134 (OX40) (BD Pharmigen, clone: ACT35), APC-H7-conjugated anti-human CD4 (BD Pharmigen, clone: RPA-T4), PE-conjugated anti-human CD69 (Miltenyi, clone: FN50), PE-Cy 7-conjugated anti-human CD8 (BD Horizon, clone: RPA-T8).

    Techniques:

    T cell comparison in IFN- and OCRE-treated patients with multiple sclerosis (pwMS) undergoing BNT162b2 mRNA SARS-CoV-2 vaccination. Fold change over basal [calculated as the ratio between the percentage of cells at T1 and T2 compared to baseline (T0)] of (a) CD8 + , (b) CD154 + , (c) CD69 + , (d) OX40 + , (e) TIGIT + , (f) CD62L + and (g) CD4 + , (h) CD154 + , (i) CD69 + , (j) OX40 + , (k) TIGIT + , (l) CD62L + cells in IFN (●) and OCRE (▲) -treated pwMS. Data are presented as median values. Statistical analysis was performed by using the Kruskal-Wallis test. * p ≤ 0.05, ** p ≤ 0.01.

    Journal: Frontiers in Immunology

    Article Title: Multiple sclerosis patients under treatment with interferon β1-a or ocrelizumab exhibit different T and B cell responses to SARS-CoV-2 vaccine

    doi: 10.3389/fimmu.2026.1773417

    Figure Lengend Snippet: T cell comparison in IFN- and OCRE-treated patients with multiple sclerosis (pwMS) undergoing BNT162b2 mRNA SARS-CoV-2 vaccination. Fold change over basal [calculated as the ratio between the percentage of cells at T1 and T2 compared to baseline (T0)] of (a) CD8 + , (b) CD154 + , (c) CD69 + , (d) OX40 + , (e) TIGIT + , (f) CD62L + and (g) CD4 + , (h) CD154 + , (i) CD69 + , (j) OX40 + , (k) TIGIT + , (l) CD62L + cells in IFN (●) and OCRE (▲) -treated pwMS. Data are presented as median values. Statistical analysis was performed by using the Kruskal-Wallis test. * p ≤ 0.05, ** p ≤ 0.01.

    Article Snippet: After the stimulation, cells were washed and surface stained for 20 minutes at 4 °C with the following antibodies: BV510-conjugated anti-human CD3 (Miltenyi, clone: BW264/56), APC-conjugated anti-human CD134 (OX40) (BD Pharmigen, clone: ACT35), APC-H7-conjugated anti-human CD4 (BD Pharmigen, clone: RPA-T4), PE-conjugated anti-human CD69 (Miltenyi, clone: FN50), PE-Cy 7-conjugated anti-human CD8 (BD Horizon, clone: RPA-T8).

    Techniques: Comparison

    CD8 + and CD4 + T cell response in INF-treated patients with multiple sclerosis (pwMS) before and after BNT162b2 mRNA SARS-CoV-2 vaccination. Cumulative data of flow cytometry analysis of spike-specific CD8 + and CD4 + T cells measured as the percentage of activated (a) CD69 + CD137 + and (d) CD154 + OX40 + T cells, respectively. Intracellular cytokines evaluation of (b) INF-γ and (c) TNF-α in CD8 + antigen-specific T cells and (e) IFN-γ, (f) TNF-α, and (g) IL-2 in CD4 + antigen-specific T cells. Analysis was performed after stimulation for 18 hours at 37 °C with a peptide pool spanning the entire Spike sequence. Data are presented as median values of at least n=4 subjects. Statistical analysis was performed by using the Mann-Whitney U -test (two tails); * p ≤ 0.05, ** p ≤ 0.01.

    Journal: Frontiers in Immunology

    Article Title: Multiple sclerosis patients under treatment with interferon β1-a or ocrelizumab exhibit different T and B cell responses to SARS-CoV-2 vaccine

    doi: 10.3389/fimmu.2026.1773417

    Figure Lengend Snippet: CD8 + and CD4 + T cell response in INF-treated patients with multiple sclerosis (pwMS) before and after BNT162b2 mRNA SARS-CoV-2 vaccination. Cumulative data of flow cytometry analysis of spike-specific CD8 + and CD4 + T cells measured as the percentage of activated (a) CD69 + CD137 + and (d) CD154 + OX40 + T cells, respectively. Intracellular cytokines evaluation of (b) INF-γ and (c) TNF-α in CD8 + antigen-specific T cells and (e) IFN-γ, (f) TNF-α, and (g) IL-2 in CD4 + antigen-specific T cells. Analysis was performed after stimulation for 18 hours at 37 °C with a peptide pool spanning the entire Spike sequence. Data are presented as median values of at least n=4 subjects. Statistical analysis was performed by using the Mann-Whitney U -test (two tails); * p ≤ 0.05, ** p ≤ 0.01.

    Article Snippet: After the stimulation, cells were washed and surface stained for 20 minutes at 4 °C with the following antibodies: BV510-conjugated anti-human CD3 (Miltenyi, clone: BW264/56), APC-conjugated anti-human CD134 (OX40) (BD Pharmigen, clone: ACT35), APC-H7-conjugated anti-human CD4 (BD Pharmigen, clone: RPA-T4), PE-conjugated anti-human CD69 (Miltenyi, clone: FN50), PE-Cy 7-conjugated anti-human CD8 (BD Horizon, clone: RPA-T8).

    Techniques: Flow Cytometry, Sequencing, MANN-WHITNEY

    CD8 + and CD4 + T cell response in OCRE-treated patients with multiple sclerosis (pwMS) before and after BNT162b2 mRNA SARS-CoV-2 vaccination. Cumulative data of flow cytometry analysis of spike-specific CD8 + and CD4 + T cells measured as the percentage of activated (a) CD69 + CD137 + and (d) CD154 + OX40 + T cells, respectively. Intracellular cytokines evaluation of (b) IFN-γ and (c) TNF-α in CD8 + antigen-specific T cells and (e) IFN-γ, (f) TNF-α, and (g) IL-2 in CD4 + antigen-specific T cells. Analysis was performed after stimulation for 18 hours at 37 °C with a peptide pool spanning the entire Spike sequence. Data are presented as median values of at least n=3 subjects. Statistical analysis was performed by using the Mann-Whitney U -test (two tails); * p ≤ 0.05, ** p ≤ 0.01.

    Journal: Frontiers in Immunology

    Article Title: Multiple sclerosis patients under treatment with interferon β1-a or ocrelizumab exhibit different T and B cell responses to SARS-CoV-2 vaccine

    doi: 10.3389/fimmu.2026.1773417

    Figure Lengend Snippet: CD8 + and CD4 + T cell response in OCRE-treated patients with multiple sclerosis (pwMS) before and after BNT162b2 mRNA SARS-CoV-2 vaccination. Cumulative data of flow cytometry analysis of spike-specific CD8 + and CD4 + T cells measured as the percentage of activated (a) CD69 + CD137 + and (d) CD154 + OX40 + T cells, respectively. Intracellular cytokines evaluation of (b) IFN-γ and (c) TNF-α in CD8 + antigen-specific T cells and (e) IFN-γ, (f) TNF-α, and (g) IL-2 in CD4 + antigen-specific T cells. Analysis was performed after stimulation for 18 hours at 37 °C with a peptide pool spanning the entire Spike sequence. Data are presented as median values of at least n=3 subjects. Statistical analysis was performed by using the Mann-Whitney U -test (two tails); * p ≤ 0.05, ** p ≤ 0.01.

    Article Snippet: After the stimulation, cells were washed and surface stained for 20 minutes at 4 °C with the following antibodies: BV510-conjugated anti-human CD3 (Miltenyi, clone: BW264/56), APC-conjugated anti-human CD134 (OX40) (BD Pharmigen, clone: ACT35), APC-H7-conjugated anti-human CD4 (BD Pharmigen, clone: RPA-T4), PE-conjugated anti-human CD69 (Miltenyi, clone: FN50), PE-Cy 7-conjugated anti-human CD8 (BD Horizon, clone: RPA-T8).

    Techniques: Flow Cytometry, Sequencing, MANN-WHITNEY